Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
Posted inCardiology Hematology-Oncology news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer alternative for high-risk geriatric populations.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.
Aspirin in the Healthy Elderly: ASPREE’s Clear Message — No Benefit, Higher Bleeding, and Unexpected Cancer Signal
Posted inCardiology Internal Medicine news

Aspirin in the Healthy Elderly: ASPREE’s Clear Message — No Benefit, Higher Bleeding, and Unexpected Cancer Signal

ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑related death; extended follow‑up confirmed no long‑term MACE benefit.
Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy
Posted inCardiology Clinical Updates news Specialties

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy

Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic events across risk strata.